NanoBio Corporation Announces First Patients Vaccinated in Phase 1b Intranasal Influenza Vaccine Study

ANN ARBOR, Mich.--(BUSINESS WIRE)--Building upon a series of successful preclinical and clinical studies, NanoBio Corporation today announced the initiation of a second tolerability and immunogenicity study designed to test and further optimize its novel nanoemulsion-based intranasal vaccine adjuvant.

MORE ON THIS TOPIC